Press release
Asthma Therapeutics Market Size in 7MM was ~USD 20,633 million in 2023 and is anticipated to grow with a significant CAGR of 1.6% by 2034, estimates DelveInsight
DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of asthma, historical and forecasted epidemiology, as well as the asthma therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.Discover which therapies are expected to grab the Asthma Therapeutics Market Share @ Asthma Market Outlook [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Asthma Therapeutics Market Report
* In June 2025, Amgen announced a Phase 2 study to assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma.
* In June 2025, Teva Branded Pharmaceutical Products R&D Inc. conducted a study is to assess the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs).
* In 2023, there were an estimated 55 million diagnosed prevalent cases of asthma across the 7MM, with the number expected to rise by 2034.
* In 2023, the US recorded approximately 26 million diagnosed prevalent cases of asthma, this figure projected to grow by 2034.
* According to DelveInsight analysis, there were around 4.8 million pediatrics and 21.2 million adults cases of asthma in the US in 2023, with numbers expected to rise by 2034.
* As per DelveInsight analysis, among EU4 and the UK, the highest number of asthma cases was observed in the UK (8.4 million), followed by Germany (4.9 million) and France (4.7 million), in 2023. These cases are expected to change during the forecast period (2024-2034).
* As per DelveInsight analysis, among EU4 and the UK, intermittent cases were the highest e.g. Germany accounted for around 1.7 million intermittent cases, followed by moderate, mild, and severe, respectively, in 2023.
* In Japan, based on severity cases by type, highest cases were diagnosed for type-2 inflammation, around 175 thousand in 2023, while non-type-2 inflammation were observed among 39 thousand patients. These cases are expected to change during the forecast period (2024-2034).
* In Japan, the highest number of diagnosed asthma cases in 2023 was recorded among females, reaching approximately 2.6 cases
* The leading Asthma Companies such as GlaxoSmithKline, Teva Pharmaceuticals, Launch Therapeutics, AB Science, AstraZeneca, Areteia Therapeutics, Knopp Biosciences, Palobiofarma SL, Pivotal S.L., Sterna Biologicals, Sanofi, Connect Biopharma and others.
* Promising Asthma Pipeline Therapies such as NEXThaler 100/6 mcg DPI, Flixotide Accuhaler 500 mcg, FOSTER, Seretide, Roflumilast, Nebulized budesonide and others.
Stay ahead in the Asthma Therapeutics Market with DelveInsight's Strategic Report @ Asthma Treatment Market [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Asthma Epidemiology Segmentation in the 7MM
* Total Asthma Diagnosed Prevalent Cases
* Asthma Age-specific Cases
* Asthma Gender-specific Cases
* Asthma Severity-specific Cases
* Asthma Type-specific Severity Cases
Download the report to understand which factors are driving Asthma Epidemiology trends @ Asthma Prevalence [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Asthma Marketed Drugs
* AIRSUPRA (albuterol and budesonide): AstraZeneca/Avillion
AIRSUPRA (albuterol/budesonide), developed by AstraZeneca and Avillion, is a first-in-class, FDA-approved rescue inhaler for asthma in patients aged 18 and older. Combining albuterol, a bronchodilator, and budesonide, an anti-inflammatory corticosteroid, it offers dual-action relief from asthma symptoms using AstraZeneca's Aerosphere delivery technology. Approved in January 2023 and commercially available in the US since January 2024, AIRSUPRA provides as-needed treatment to prevent bronchoconstriction and reduce exacerbation risks. This innovative therapy stems from AstraZeneca's 2013 acquisition of Pearl Therapeutics and a 2018 agreement with Avillion, which sponsored its clinical development. With its unique fixed-dose combination, AIRSUPRA marks a significant advancement in asthma management by addressing both bronchospasm and inflammation in a single inhaler.
* TEZSPIRE (tezepelumab): Amgen/AstraZeneca
TEZSPIRE (tezepelumab), developed by AstraZeneca and Amgen, is a first-in-class monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a key driver of severe asthma inflammation. By acting at the top of the inflammatory cascade, it helps manage airway hyper-responsiveness and various types of inflammation, regardless of biomarker levels. Approved in the US (2021), EU (2022), and Japan (2022), it is indicated as an add-on maintenance treatment for severe asthma in patients aged 12 and older. Administered subcutaneously at 210 mg every four weeks, TEZSPIRE is available in prefilled pens, syringes, and vials. Regulatory milestones include Breakthrough Therapy Designation (2018), Priority Review (2021), and recent approvals for self-administration devices. Under a collaboration agreement, AstraZeneca oversees development, while Amgen manages manufacturing, with shared commercialization responsibilities.
* CINQAIR/CINQAERO (reslizumab): Teva Pharmaceuticals
CINQAIR/CINQAERO (reslizumab), developed by Teva Pharmaceuticals, is a humanized IL-5 antagonist monoclonal antibody approved in 2016 for severe eosinophilic asthma in adults. It reduces eosinophilic inflammation by preventing IL-5 from binding to its receptor, improving lung function and reducing exacerbations. Administered via intravenous infusion (3 mg/kg every 4 weeks), it is marketed as CINQAIR in the US and CINQAERO in Europe. Regulatory approvals were based on Teva's BREATH program, with commercialization beginning in 2016 and NICE recommending its use in 2017 for severe cases unresponsive to other therapies.
Asthma Emerging Drugs
* Depemokimab (GSK3511294): GlaxoSmithKline
GSK3511294 (depemokimab), which is being developed to treat severe eosinophilic asthma, is a humanized anti-interleukin (IL)-5 monoclonal antibody. As a new biological entity, it is engineered to ensure high affinity and long-acting suppression of IL-5 functions. IL-5 is cytokines responsible for the proliferation, activation, and survival of eosinophils, thus making them a proven treatment target for severe asthma patients with higher levels of eosinophils. Depemokimab, with an extended half-life and improved IL-5 affinity compared to other approved therapies, is the first biologic to be administered subcutaneously once every 26 weeks.
* Masitinib: AB Science
Masitinib, a first-in-class oral drug for severe asthma, selectively targets the mast cells by inhibiting tyrosine kinases (c-Kit, LYN, FYN) and PDGFR signaling that regulates the associated proinflammatory cytokines and other mediators which affect airway smooth muscle proliferation, bronchoconstriction, inflammation, and airway remodeling.
* BREZTRI AEROSPHERE (PT010): AstraZeneca/Amgen
PT010, being developed by AstraZeneca, is a fixed-dose combination of micronized budesonide, an inhaled corticosteroid (ICS), micronized glycopyrrolate (an anticholinergic), and micronized formoterol fumarate, a LABA, for oral inhalation administered via a pressurized metered-dose inhaler (pMDI) using Aerosphere delivery technology. Budesonide is a potent glucocorticosteroid with dose-dependent anti-inflammatory action in the airways. Glycopyrronium, a LAMA (anticholinergic agent), exhibits reversible competitive inhibition of muscarinic receptors, and it inhibits the muscarinic M3 receptor in the smooth muscle, leading to bronchodilation. Formoterol, a selective LABA, has a higher binding selectivity to Ss2-adrenoreceptor over Ss1-adrenoreceptors, and it rapidly relaxes the bronchial smooth muscle in patients with reversible airway obstruction.
To learn more about Asthma Treatment guidelines, visit @ Asthma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Asthma Companies
GlaxoSmithKline, Teva Pharmaceuticals, Launch Therapeutics, AB Science, AstraZeneca, Areteia Therapeutics, Knopp Biosciences, Palobiofarma SL, Pivotal S.L., Sterna Biologicals, Sanofi, Connect Biopharma and others.
Asthma Drugs Market Insights
The current asthma treatment is not curative but aims to control symptoms and minimize future risks. Asthma is treated with various medications that can be divided into two main classes: anti-inflammatory drugs and bronchodilators. Anti-inflammatory drugs, such as inhaled corticosteroids, leukotriene modifiers, and mast cell stabilizers, suppress the inflammation that narrows the airways. Bronchodilators, including beta-agonists, anticholinergics, and methylxanthines, help relax and widen the airways. Combination inhalers containing both a corticosteroid and a bronchodilator are also commonly used. Newer biologic medications that target specific immune pathways may be used for severe, eosinophilic asthma.
Asthma Market Outlook
Asthma is a common, non-communicable, and variable serious global health problem that can result in episodic or persistent respiratory symptoms (e.g., shortness of breath, wheezing, chest tightness, and cough) and airflow limitation, the latter being due to bronchoconstriction, airway wall thickening, and increased mucus. The goal of treatment is to minimize symptom burden (i.e., maintain normal activity levels while maintaining good symptom control) and reduce the possibility of adverse events such as fixed airflow limitation, exacerbations, and therapeutic side effects. Guidelines-based asthma management emphasizes the severity of the condition and selecting the best medical treatment to manage symptoms and lower the likelihood of exacerbations.
Learn more about the FDA-approved drugs for Asthma @ Drugs for Asthma Treatment [https://www.delveinsight.com/sample-request/asthma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Asthma Market Report
* Coverage- 7MM
* Study Period- 2020-2034
* Asthma Companies- GlaxoSmithKline, Teva Pharmaceuticals, Launch Therapeutics, AB Science, AstraZeneca, Areteia Therapeutics, Knopp Biosciences, Palobiofarma SL, Pivotal S.L., Sterna Biologicals, Sanofi, Connect Biopharma and others.
* Asthma Pipeline Therapies- NEXThaler 100/6 mcg DPI, Flixotide Accuhaler 500 mcg, FOSTER, Seretide, Roflumilast, Nebulized budesonide and others.
* Asthma Market Dynamics: Asthma Market Drivers and Barriers
* Asthma Market Access and Reimbursement, Unmet Needs and Future Perspectives
Table of Contents
1. Key Insights
2. Asthma Market Report Introduction
3. Asthma Market Overview at a Glance
4. Asthma Epidemiology and Market Forecast Methodology
5. Asthma Executive Summary
6. Key Events
7. Asthma Disease Background and Overview
8. Asthma Patient Journey
9. Asthma Epidemiology and Patient Population
10. Asthma Marketed Drugs
11. Emerging Asthma Drugs
12. Asthma: Market Analysis
14. Key Opinion Leaders' Views
15. Asthma SWOT Analysis
16. Asthma Unmet Needs
17. Asthma Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=asthma-therapeutics-market-size-in-7mm-was-usd-20633-million-in-2023-and-is-anticipated-to-grow-with-a-significant-cagr-of-16-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/asthma-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asthma Therapeutics Market Size in 7MM was ~USD 20,633 million in 2023 and is anticipated to grow with a significant CAGR of 1.6% by 2034, estimates DelveInsight here
News-ID: 4058250 • Views: …
More Releases from ABNewswire

Abby Yoga Studio Expands with Private Yoga Therapy Sessions
Certified Yoga Therapy instructor offers tailored Iyengar-based practices for health needs.
Image: https://www.abnewswire.com/upload/2025/10/f6b927744919d106273aa8b6f23c144c.jpg
Abbotsford, BC - Abby Yoga Studio has introduced private yoga therapy sessions, focusing on personalized assessments and adapted practices for individuals or small groups. Applying Iyengar yoga therapy principles, these one-on-one or limited-group classes address physical and emotional challenges, integrating mind-body healing to restore natural function.
Led by Eileen Millar, a Level Three certified Iyengar teacher and C-IAYT yoga therapist,…

Zil Money Launches ZilRemit as Dedicated International Payment Platform
New Standalone Platform Offers Seamless, Low-Cost Global Payments for Businesses and Personal Use, with Easy App Access and Faster Transaction Processing.
Image: https://www.abnewswire.com/upload/2025/10/491fa4dc34bd8bd434ab18aeac2e7e4f.jpg
TYLER, TX, USA - Oct 09, 2025 - Zil Money, a leading B2B payment platform, today announced the launch of ZilRemit, a dedicated platform for its international payment services. The new platform provides a focused identity for the company's high-speed, low-cost global payment solution, enabling businesses and individuals to…

Shashishekhar Ramagundam: Driving Innovation in AI and Content Discovery at ORCI …
Image: https://www.abnewswire.com/upload/2025/10/be0969e168c2d58f071b39a1d5c5c91e.jpg
Shashishekhar Ramagundam [https://www.linkedin.com/in/shashishekhar-ramagundam-051a1233b] is a computer scientist and senior IEEE member whose career has centered on advancing Machine Learning, artificial intelligence (AI) and scalable content delivery. His research and professional responsibilities directly address critical challenges in streaming media, recommendations, and enterprise-level data security, impacting both academic progress and industry practices.
Educational and Professional Background
Ramagundam earned a master's degree in computer science from Troy University, Alabama, in 2014, with academic strengths…

Conceivable's Proven Fertility Platform Delivers 260% Increase in Natural Concep …
Conceivable, the comprehensive women's health technology platform, has demonstrated remarkable clinical results with its virtual care approach, increasing the likelihood of natural conception by 260% for couples struggling with infertility. The company's integrated model combines fertility coaching, nutrition, culinary support, mental health services, and data science to address the root causes of infertility through personalized, evidence-based interventions.
Conceivable is revolutionizing fertility care with a virtual platform that has achieved what many…
More Releases for Asthma
Evolving Market Trends In The Asthma Spacers Industry: Smart Inhaler Devices Rev …
The Asthma Spacers Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Asthma Spacers Market Size During the Forecast Period?
The asthma spacers market has grown steadily, forecasted to rise from $1.88 billion in 2024 to $2.01 billion in 2025 at a CAGR…
Asthma Relief Reimagined: Trends Driving Asthma Spacer Innovation
The Business Research Company recently released a comprehensive report on the Global Asthma Spacers Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Asthma Warning Sensors Market Connected Care for Asthma: How Warning Sensors Imp …
Asthma Warning Sensors Market Market to Record an Exponential CAGR by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Asthma Warning Sensors Market Size, Share & Trends Analysis Report By Type (Wearable v/s Non-Wearable), By Technology (AI, IoT, Machine Learning, Others), By Parameter Measured (FEV1 v/s Peak Flow), By End User (Hospitals & Clinics v/s Homecare)- Market…
Asthma Spacers Market Optimizing Asthma Treatment: How Spacers are Improving Del …
Asthma Spacers Market Assessment worth $ 2.47 Billion by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Asthma Spacers Market- by Product (Space Chamber Plus, A2A Spacer, Flo-Tone CR, Able Spacer, AeroChamber, Volumatic, Vortex, OptiChamber), Application (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get a free sample copy of…
Severe Asthma Treatment Market - Revitalizing Quality of Life: Severe Asthma Tre …
Newark, New Castle, USA: The "Severe Asthma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Severe Asthma Treatment Market: https://www.growthplusreports.com/report/severe-asthma-treatment-market/8939
This latest report researches the industry structure,…
Asthma Monitoring Devices Market - Revolutionizing Asthma Care: Elevate Monitori …
Newark, New Castle, USA: The "Asthma Monitoring Devices Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Asthma Monitoring Devices Market: https://www.growthplusreports.com/report/asthma-monitoring-devices-market/8697
This latest report researches the industry structure,…